Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$169.58M$169.58M+48.2% vs Q2 2025 Net Income-$34.80M-$34.80MN/M vs Q2 2025 EPS Diluted-$0.37-$0.37N/M vs Q2 2025 Operating Income$3,954,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin2.3%+13.4 pt vs Q2 2025
Net margin-20.5%−9.4 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end